 Your new post is loading...
Your new post is loading...
|
Scooped by
Gerry Post
|
"Oncologists are in a very particular predicament right now," says Dr. Siddhartha Mukherjee.
|
|
Scooped by
Gerry Post
|
Man's best friends are providing hope for new osteosarcoma treatments.
|
|
Scooped by
Gerry Post
|
|
|
Scooped by
Gerry Post
|
Veterinary news for UK small animal, farm animal and equine veterinary surgeons.
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.
Via Krishan Maggon
The German biotech BioNTech has raised a huge Series B of €289.5M ($325M) to develop individualized cancer vaccines based on mRNA.
Via Krishan Maggon
|
|
Scooped by
Gerry Post
|
The FDA is expanding its private sector collaborations to advance its understanding of real world data and evidence. Does this mean that it will begin to approve new drugs and expand labeling on the basis of physician and patient experience, rather than solely on randomized clinical trial data?
|
|
Scooped by
Gerry Post
|
|
|
Scooped by
Gerry Post
|
Dogs started receiving a vaccine against cancer this week in a clinical trial at UW-Madison. If the vaccine works in dogs, it may not only provide a new strategy for addressing a critical canine health concern, it might also work in people.
|
|
Scooped by
Gerry Post
|
For World Cancer Day, here's a collection of articles that illustrate the importance of evolution and ecology for understanding and combating cancer.
|
|
Scooped by
Gerry Post
|
“Our results are consistent and repeatable.”
|
|
Scooped by
Gerry Post
|
Despite skepticism, researchers remain doggedly determined to nosing out disease.
|
|
Scooped by
Gerry Post
|
The field of comparative oncology leverages other mammals’ cancers, even some from cats and horses, to develop better human treatments.
|
|
|
Scooped by
Gerry Post
|
Bioengineering is changing the landscape of health and health care. Integrating it into the world of scientific discovery will take some work.
|
|
Scooped by
Gerry Post
|
Researchers find more evidence of a possible connection between persistent bacterial infection and blood vessel cancer in dogs.
|
|
Scooped by
Gerry Post
|
Dr. Charles Sawyers played a major role in the development of the blockbuster drugs Gleevec for leukemia and Xtandi for prostate cancer.
|
|
Scooped by
Gerry Post
|
There’s a strong chance your aging dog will get cancer—but your pupper could also help humans survive it.
Background Targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy (CRI) or not are commonly used in patients with melanoma brain metastases, but studies that directly compare these strategies are lacking. The current meta‐analysis aimed to better elucidate their activity and efficacy. Methods A systematic search of MEDLINE, Embase, and conference proceedings up to January 2019 was performed to identify trials investigating combination TT, monotargeted TT (mono TT), MI, CMI, and CRI in melanoma brain metastases. The outcomes considered were progression‐free survival (PFS), overall survival (OS), and the objective response rate (ORR) as evaluated at both intracranial and extracranial sites. Random effects models were used to compare the different therapeutic strategies. Results A total of 15 trials were included that provided 1132 patients for analyses. CMI demonstrated a statistically significant better OS compared with MI (P = .03, P = .05, and P = .03, respectively, at 6 months, 18 months, and 24 months) and combination TT (P = .04 and P = .03, respectively, at 18 months and 24 months). CMI demonstrated a statistically significant better PFS compared with combination TT (P < .001 at 12 months and 18 months), MI (P = .02, P < .02, and P = .05, respectively, at 6 months, 12 months, and 18 months), and mono TT (P < .001 at 6 months, 12 months, and 18 months). The intracranial objective response rate was higher with CMI compared with mono TT (P < .001) and MI (P < .001), whereas there was no difference between CMI and combination TT. Conclusions The results of the current meta‐analysis suggested that CMI increases long‐term PFS and OS compared with MI and combination TT. Combination TT and CMI are associated with a similar intracranial response rate. The role of systemic therapy in combination with radiotherapy remains to be better elucidated.
Via Krishan Maggon
“With the development of novel targeted therapies for patients with colorectal cancer, comes a wealth of new, and increasingly complex information on biomarkers.In this Review, the authors describe this increased complexity, with a focus on interactions between more than one biomarker and the implications...
Via Krishan Maggon
|
|
Scooped by
Gerry Post
|
Yale Medicine physicians have researched what happens when patients forego medical cancer treatment in hopes of finding a natural cure.
|
|
Scooped by
Gerry Post
|
Cancers occur in domestic animals, particularly household pets, at almost the same level as they do in humans. The methods of treating our mammalian companions do not differ drastically when compared to how we treat human oncology patients — namely via the use of chemotherapy drugs. These drugs are cytotoxic and anti-neoplastic, posing considerable risk …
|
|
Scooped by
Gerry Post
|
|
|
Scooped by
Gerry Post
|
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
|
|
Scooped by
Gerry Post
|
Jason Sheltzer, a research fellow at Cold Spring Harbor Laboratory, and his team have examined prostate, breast, lung and other forms of cancer, with an emphasis toward prognosis and predictability.
|
|
Scooped by
Gerry Post
|
Who needs lab rats when you’ve got dogs?
|
Scoop.it!
